Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

Publisher： John Wiley & Sons Inc

E-ISSN： 1743-7563|11|2|121-128

ISSN： 1743-7555

Source： ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.11, Iss.2, 2015-06, pp. : 121-128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inflammation‐Related Genetic Variations and Survival in Patients With Advanced Non–Small Cell Lung Cancer Receiving First‐Line Chemotherapy

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 350-355

Karger

Access to resources Recommend Favorite

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 710-718

Karger

Access to resources Recommend Favorite

Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 665-670

Karger

Access to resources Recommend Favorite